Clinical Trial Update: Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lenvatinib with pembrolizumab in Black patients with mismatch repair-proficient recurrent endometrial cancer has been terminated. Res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Endometrial Cancer, Mismatch Repair-Proficient | Phase 2 | Status: TERMINATED | Results posted: 2025-10-02